{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:20:49Z","timestamp":1785014449407,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL138154"],"award-info":[{"award-number":["K23HL138154"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32NR016913"],"award-info":[{"award-number":["T32NR016913"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BOMBER19R0"],"award-info":[{"award-number":["BOMBER19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RAMOS17A0"],"award-info":[{"award-number":["RAMOS17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RAMOS20A0-KB"],"award-info":[{"award-number":["RAMOS20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:45:53Z","timestamp":1700905553000},"page":"161-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-9338","authenticated-orcid":false,"given":"Eliana R.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-3958","authenticated-orcid":false,"given":"Lauren E.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-4165","authenticated-orcid":false,"given":"Tijana","family":"Milinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4610-4769","authenticated-orcid":false,"given":"Nora","family":"Burdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Pilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Dunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-9769","authenticated-orcid":false,"given":"Siddhartha G.","family":"Kapnadak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2023.11.008_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2023.11.008_bib0002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1742395318772647","article-title":"Adult patients' experiences of symptom management during pulmonary exacerbations in cystic fibrosis: a thematic synthesis of qualitative research","volume":"15","author":"Schmid-Mohler","year":"2019","journal-title":"Chronic Illn"},{"issue":"19","key":"10.1016\/j.jcf.2023.11.008_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2023.11.008_bib0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.11.008_bib0006","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.11.008_bib0007","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.008_bib0008","unstructured":"Cystic Fibrosis Foundation. Patient registry annual data report, https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf; 2021 [accessed 30 June 2023]."},{"issue":"6","key":"10.1016\/j.jcf.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jcf.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2017.04.004","article-title":"Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis","volume":"16","author":"VanDevanter","year":"2017","journal-title":"J. Cyst Fibros."},{"issue":"6","key":"10.1016\/j.jcf.2023.11.008_bib0011","doi-asserted-by":"crossref","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"10.1016\/j.jcf.2023.11.008_bib0012","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"58","author":"McCoy","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2023.11.008_bib0013","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in france","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:25Z","timestamp":1767240685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323016788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323016788"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}